MannKind (MNKD) Competitors $5.31 -0.18 (-3.28%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$5.34 +0.04 (+0.66%) As of 10/24/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MNKD vs. ALKS, LGND, FOLD, CLDX, BCRX, NVAX, OPK, DVAX, INVA, and ZBIOShould you be buying MannKind stock or one of its competitors? The main competitors of MannKind include Alkermes (ALKS), Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), Celldex Therapeutics (CLDX), BioCryst Pharmaceuticals (BCRX), Novavax (NVAX), OPKO Health (OPK), Dynavax Technologies (DVAX), Innoviva (INVA), and Zenas BioPharma (ZBIO). These companies are all part of the "biotechnology" industry. MannKind vs. Its Competitors Alkermes Ligand Pharmaceuticals Amicus Therapeutics Celldex Therapeutics BioCryst Pharmaceuticals Novavax OPKO Health Dynavax Technologies Innoviva Zenas BioPharma Alkermes (NASDAQ:ALKS) and MannKind (NASDAQ:MNKD) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk. Which has higher earnings & valuation, ALKS or MNKD? Alkermes has higher revenue and earnings than MannKind. Alkermes is trading at a lower price-to-earnings ratio than MannKind, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlkermes$1.56B3.16$367.07M$2.0814.33MannKind$301.74M5.40$27.59M$0.1148.27 Do analysts recommend ALKS or MNKD? Alkermes currently has a consensus target price of $42.83, indicating a potential upside of 43.74%. MannKind has a consensus target price of $10.86, indicating a potential upside of 104.47%. Given MannKind's higher possible upside, analysts plainly believe MannKind is more favorable than Alkermes.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alkermes 0 Sell rating(s) 3 Hold rating(s) 9 Buy rating(s) 3 Strong Buy rating(s) 3.00MannKind 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.89 Does the media refer more to ALKS or MNKD? In the previous week, Alkermes had 15 more articles in the media than MannKind. MarketBeat recorded 19 mentions for Alkermes and 4 mentions for MannKind. MannKind's average media sentiment score of 1.22 beat Alkermes' score of 0.62 indicating that MannKind is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alkermes 6 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MannKind 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals hold more shares of ALKS or MNKD? 95.2% of Alkermes shares are held by institutional investors. Comparatively, 49.5% of MannKind shares are held by institutional investors. 4.4% of Alkermes shares are held by insiders. Comparatively, 2.7% of MannKind shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has more volatility & risk, ALKS or MNKD? Alkermes has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500. Comparatively, MannKind has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500. Is ALKS or MNKD more profitable? Alkermes has a net margin of 23.15% compared to MannKind's net margin of 10.87%. Alkermes' return on equity of 24.86% beat MannKind's return on equity.Company Net Margins Return on Equity Return on Assets Alkermes23.15% 24.86% 17.14% MannKind 10.87%-32.60%7.81% SummaryAlkermes beats MannKind on 12 of the 17 factors compared between the two stocks. Get MannKind News Delivered to You Automatically Sign up to receive the latest news and ratings for MNKD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MNKD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MNKD vs. The Competition Export to ExcelMetricMannKindMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.68B$3.44B$6.23B$10.67BDividend YieldN/A2.26%5.71%4.82%P/E Ratio48.2824.2730.1530.17Price / Sales5.40489.23587.79130.40Price / Cash39.5645.5737.0161.44Price / Book-18.3110.4012.046.60Net Income$27.59M-$52.62M$3.32B$276.82M7 Day Performance-2.93%2.09%1.89%2.58%1 Month Performance-0.38%12.32%7.68%3.76%1 Year Performance-18.81%14.12%56.01%33.84% MannKind Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MNKDMannKind3.6075 of 5 stars$5.31-3.3%$10.86+104.5%-17.5%$1.68B$301.74M48.28400Positive NewsALKSAlkermes4.6066 of 5 stars$30.98+2.4%$42.00+35.6%+11.0%$5.00B$1.56B14.891,800Trending NewsUpcoming EarningsAnalyst UpgradeAnalyst RevisionLGNDLigand Pharmaceuticals3.7861 of 5 stars$186.74+2.8%$176.50-5.5%+68.5%$3.56B$167.13M-46.6980Positive NewsFOLDAmicus Therapeutics4.3774 of 5 stars$8.44+5.0%$15.88+88.1%-26.3%$2.48B$528.29M-70.33480News CoverageAnalyst ForecastCLDXCelldex Therapeutics1.7898 of 5 stars$27.67+3.1%$43.78+58.2%-5.0%$1.78B$7.02M-9.19150News CoverageAnalyst ForecastGap UpBCRXBioCryst Pharmaceuticals4.3096 of 5 stars$6.93+4.5%$19.18+176.8%-12.0%$1.39B$450.71M-38.50530Analyst ForecastNVAXNovavax4.5823 of 5 stars$8.79+8.5%$9.80+11.5%-14.1%$1.32B$682.16M3.861,990Trending NewsAnalyst ForecastAnalyst RevisionGap UpOPKOPKO Health4.2832 of 5 stars$1.53+0.7%$2.63+71.6%+7.1%$1.21B$713.10M0.002,997News CoverageDVAXDynavax Technologies4.5495 of 5 stars$10.06+2.3%$24.33+141.9%-3.6%$1.15B$277.25M-21.87350News CoverageAnalyst ForecastINVAInnoviva4.5295 of 5 stars$17.21-0.3%$37.60+118.5%-10.6%$1.09B$358.71M55.52100Analyst UpgradeZBIOZenas BioPharma1.8888 of 5 stars$26.15+9.2%$38.33+46.6%N/A$1.01B$5M0.00N/APositive News Related Companies and Tools Related Companies Alkermes Alternatives Ligand Pharmaceuticals Alternatives Amicus Therapeutics Alternatives Celldex Therapeutics Alternatives BioCryst Pharmaceuticals Alternatives Novavax Alternatives OPKO Health Alternatives Dynavax Technologies Alternatives Innoviva Alternatives Zenas BioPharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MNKD) was last updated on 10/25/2025 by MarketBeat.com Staff From Our PartnersNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MannKind Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share MannKind With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MNKD Stock Alerts